Table II.
Human serum albumin derived tryptic peptides containing piperacillin-modified lysine residues
| Lysine | Peptide | Cyclized hapten | Hydrolyzed hapten |
|---|---|---|---|
| 4 | DAHK*SEVAHR | X | √ |
| 12 | FK*DLGEENFK | √ | √ |
| 137 | K*YLYEIAR | X | √ |
| 162 | YK*AAFTECCQAADK | X | √ |
| 190 | LDELRDEGK*ASSAK | √ | √ |
| 195 | ASSAK*QR | X | √ |
| 199 | LK*CASLQK | √ | √ |
| 212 | AFK*AWAVAR | √ | √ |
| 351 | LAK*TYETTLEK | √ | √ |
| 432 | NLGK*VGSK | √ | √ |
| 525 | K*QTALVELVK | √ | √ |
| 541 | ATK*EQLK | √ | √ |
| 545 | EQLK*AVMDDFAAFVEK | X | √ |
Piperacillin:albumin ratio 50:1; incubation time 24 h.
*
indicates site of piperacillin modification